I want to donate

The Research Group in Radiation Oncology and Medical Physics of Girona (ONCORFIM Girona) is a multidisciplinary group whose mission is to improve oncological outcomes and quality of life of our patients by applying new technologies.

The way to achieve this goal, will be from the following key points for us.

  1. Minimize the dose received in critical organs and improve clinical outcomes.
  2. Predict response and toxicity to radiotherapy treatment.
  3. Use new digital technologies to achieve the previously described (ICOnnecta't).
Main lines of research

Line 1: Prevention of cardiotoxicity and radiotherapy in breast cancer.

Prevention of cardiotoxicity in breast cancer patients undergoing cardiotoxic treatments such as radiotherapy (Arantxa Eraso).

Cardiotoxicity in external radiotherapy: clinical impact of the dose delivered (Ingrid Romera).

The following projects are underway within this line:

  • Horizon 2020 Project Medirad. Early detection of cardiovascular changes after radiotherapy in breast cancer. Reference: EARLY-HEART. Principal Investigator: Arantxa Eraso.
  • Development and clinical implementation of the DIFGI device in forced inspiration techniques maintained in left breast cancer treatments with external radiotherapy to reduce the dose to the heart. Doctoral candidate: Ingrid Romera. Thesis supervisors: Joan Carles Vilanova and Rafael Fuentes.
  • Impact of a structured physical exercise program and control of cardiovascular risk factors in the primary prevention of cardiotoxicity in breast cancer patients undergoing cardiotoxic treatments: Estudi PREV (Arantxa Eraso).

Line 2: Technological advances in radiotherapy (ablative radiotherapy, intraoperative radiotherapy techniques, new techniques and quality in radiotherapy).

  • Use of Intraoperative Radiotherapy in breast neoplasia. Reference: RIOMA. Principal Investigator: Arantxa Eraso.
  • Phase II trial of Electronic Brachytherapy in the post-surgical treatment of endometrial cancer (Hugo Rosales and Ester Oliva).
  • Ablative radiotherapy in different locations, the most innovative being the Pancreatic SBRT (Eugeni Canals).
  • Dose determination, technology and quality in external radiotherapy (Diego Jurado Bruggeman).
  • Clinical impact of dose calculation in external radiotherapy and associated technological and quality assurance aspects (Carles Muñoz Montplet).

Line 3: Biomarkers of response to radiotherapy.

  • Radiogenomics: identification of biomarkers by genome-wide association studies (GWAS) and exome sequencing (WES) in extreme phenotypes.
  • Radiosensitivity studies in cancer patients at high risk of toxicity. Reference: PRED-RAD. Collaborating researchers: Arantxa Eraso, Rafael Fuentes and Àlvar Roselló.

Line 4: e-Health and humanization in the Radiation Oncology process.

  • Online screening and monitoring of symptomatology secondary to Radiation therapy treatment of digestive tumors: a prospective controlled clinical trial.
  • Prostate Cancer Outcomes Global initiative to compare and reduce variation in localized prostate cancer. Reference: PCO-CRV. Principal Investigator: Àlvar Roselló.

IROCATES: Quality improvement in Radiation Oncology through Clinical Audits. Principal Investigators: Carles Muñoz and Àlvar Roselló.

Strategic objectives

The objective of the group is to conduct research in the hospital setting in an area in which technological advances are oriented towards the modification of clinical practice towards personalized and precision medicine: Treatment for the right patient vs. treatment for a disease.


Rubió-Casadevall J, Ciurana E, Puigdemont M, Sanvisens A, Marruecos J, Miró J, Urban A, Palhua RL, Martín-Romero F, Ortiz-Duran MR, Marcos-Gragera R

Population-Based Analysis of Trends in Incidence and Survival of Human Papilloma Virus-Related Oropharyngeal Cancer in a Low-Burden Region of Southern Europe.


Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí O, Martinez Garcia M, Mallo M, Gut M, Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T, Oleaga L, Gil-Gil MJ, de Quintana-Schmidt C, Valduvieco I, Martinez-Cardus A, Bellosillo B, Muñoz-Mármol AM, Esteve A, Domenech M, Camins A, Craven-Bartle J, Villa S, Marruecos J, Domenech S, de la Iglesia N, Balana C

RNA-Sequencing and immunohistochemistry reveal ZFN7 as a stronger marker of survival than molecular subtypes in G-CIMP-negative glioblastoma.


Rubió-Casadevall J, Galceran J, Ameijide A, Puigdemont M, Llauradó L, Marruecos J, Izquierdo A, Carulla M, Borràs JL, Marcos-Gragera R, Gumà J

Population-based risk assessment of second primary cancers following a first head and neck cancer: patterns of association and difficulties of its analysis.


Niksic M, Redondo-Sanchez D, Chang YL, Rodriguez-Barranco M, Exposito-Hernandez J, Marcos-Gragera R, Oliva-Poch E, Bosch-Barrera J, Sanchez MJ, Luque-Fernandez MA

The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study.

Bmc Cancer, 2021, 21, 1048-1048

Muñoz-Montplet C, Fuentes-Raspall R, Jurado-Bruggeman D, Agramunt-Chaler S, Onsès-Segarra A, Buxó M

Dosimetric Impact of Acuros XB Dose-to-Water and Dose-to-Medium Reporting Modes on Lung Stereotactic Body Radiation Therapy and Its Dependency on Structure Composition.

Advances in Radiation Oncology, 2021, 6, 100722-100722

Martínez-Trufero J, Lozano Borbalas A, Pajares Bernad I, Taberna Sanz M, Ortega Izquierdo E, Cirauqui Cirauqui B, Rubió-Casadevall J, Plana Serrahima M, Ponce Ortega JM, Planas Toledano I, Caballero J, Marruecos Querol J, Iglesias Docampo L, Lambea Sorrosal J, Adansa JC, Mesía Nin R, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)

Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.


Lozano A, Marruecos J, Rubió J, Farré N, Gómez-Millán J, Morera R, Planas I, Lanzuela M, Vázquez-Masedo MG, Cascallar L, Giralt J, Escames G, Valentí V, Grima P, Bosser R, Tarragó C, Mesía R

Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment.


Lopes de Castro C, Fundowicz M, Roselló A, Jové J, Deantonio L, Aguiar A, Pisani C, Villà S, Boladeras A, Konstanty E, Kruszyna-Mochalska M, Milecki P, Jurado-Bruggeman D, Lencart J, Modolell I, Muñoz-Montplet C, Aliste L, Torras MG, Puigdemont M, Carvalho L, Krengli M, Guedea F, Malicki J

Results of the IROCA international clinical audit in prostate cancer radiotherapy at six comprehensive cancer centres.

SCIENTIFIC REPORTS, 2021, 11, 12323-12323

Zamora V, Garin O, Pardo Y, Pont À, Gutiérrez C, Cabrera P, Gómez-Veiga F, Pijoan JI, Litwin MS, Ferrer M, Multicentric Spanish Group of Clinically Localized Prostate Cancer

Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys.

VALUE IN HEALTH, 2021, 24, 1676-1685

Guerra-Librero A, Fernandez-Gil BI, Florido J, Martinez-Ruiz L, Rodríguez-Santana C, Shen YQ, García-Verdugo JM, López-Rodríguez A, Rusanova I, Quiñones-Hinojosa A, Acuña-Castroviejo D, Marruecos J, De Haro T, Escames G

Melatonin Targets Metabolism in Head and Neck Cancer Cells by Regulating Mitochondrial Structure and Function.

Antioxidants, 2021, 10
Competitive projects

Carles Muñoz, Ingrid Romera, Diego Jurado, Jordi Marruecos, Salvador Bou, Roger Grèbol.
Número de publicació: ES1165083
Data de publicació: 2016-09-21

Job offers


If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in